BlueYard Capital is a venture capital firm based in Berlin that invests in early-stage companies across frontier technology, decentralized systems, and biology-driven innovation. The firm is thesis-led and often backs highly unconventional ideas with long-term platform potential.

Its portfolio includes companies in areas such as RNA therapeutics and engineered biology, reflecting interest in foundational science and technical infrastructure. While not a dedicated neurotech investor, BlueYard is relevant where neurotechnology overlaps with frontier biology, computation, or enabling platform technologies.

The firm invests globally, with a strong focus on Europe and the United States. It is best suited to founders building unusually ambitious technical platforms rather than conventional healthcare products.